Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,301
  • Shares Outstanding, K 81,603
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,840 K
  • EBIT $ -28 M
  • EBITDA $ -28 M
  • 60-Month Beta 0.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.24

Options Overview Details

View History
  • Implied Volatility 156.06% ( -27.42%)
  • Historical Volatility 49.90%
  • IV Percentile 55%
  • IV Rank 12.01%
  • IV High 857.83% on 12/26/23
  • IV Low 60.32% on 06/04/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 164
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 8,086
  • Open Int (30-Day) 7,894

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.10
  • Prior Year -0.09
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4900 +2.01%
on 11/21/24
2.2400 -32.14%
on 11/07/24
-0.3900 (-20.42%)
since 10/21/24
3-Month
1.4900 +2.01%
on 11/21/24
2.6300 -42.21%
on 09/13/24
-0.5200 (-25.49%)
since 08/21/24
52-Week
0.7912 +92.11%
on 12/22/23
3.1200 -51.28%
on 06/12/24
+0.6798 (+80.91%)
since 11/21/23

Most Recent Stories

More News
Buy the Dip: 2 Cannabis ETFs Set to Benefit from Business-Friendly Policies

The recent appointment of Matt Gaetz as Attorney General has sparked controversy - and a surge in cannabis stocks. Two ETFs, AdvisorShares Pure Cannabis ETF (YOLO) and AdvisorShares Pure US Cannabis ETF...

YOLO : 2.60 (-0.77%)
CURLF : 1.9700 (-5.97%)
SNDL : 2.0100 (+2.55%)
HITI : 2.71 (+1.69%)
VFF : 0.7784 (+0.66%)
CRLBF : 1.1670 (-2.34%)
CRDL : 1.5400 (-1.28%)
TCNNF : 6.1300 (-2.85%)
VRNOF : 1.5700 (-4.27%)
GTBIF : 9.2200 (-3.96%)
MSOS : 4.55 (-4.41%)
Stocks in play: Cardiol Therapeutics Inc.

Reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact ...

CRDL : 1.5400 (-1.28%)
Five Top Heart Health Stocks to Buy Heading into 2025

Heart health statistics are startling. Not only is heart disease the leading cause of death in the United States, it also claims the life of one person every 33 seconds. Plus, the estimated global annual...

ABT : 117.01 (+0.93%)
BSX : 91.50 (+1.47%)
CRDL : 1.5400 (-1.28%)
GILD : 89.85 (+1.38%)
MDT : 84.90 (+0.94%)
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing...

CRDL.TO : 2.13 (-2.52%)
CRDL : 1.5400 (-1.28%)
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase...

CRDL.TO : 2.13 (-2.52%)
CRDL : 1.5400 (-1.28%)
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.13 (-2.52%)
CRDL : 1.5400 (-1.28%)
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.13 (-2.52%)
CRDL : 1.5400 (-1.28%)
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.13 (-2.52%)
CRDL : 1.5400 (-1.28%)
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.13 (-2.52%)
CRDL : 1.5400 (-1.28%)
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.13 (-2.52%)
CRDL : 1.5400 (-1.28%)

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 1.7617
2nd Resistance Point 1.7133
1st Resistance Point 1.6367
Last Price 1.5400
1st Support Level 1.5117
2nd Support Level 1.4633
3rd Support Level 1.3867

See More

52-Week High 3.1200
Fibonacci 61.8% 2.2304
Fibonacci 50% 1.9556
Fibonacci 38.2% 1.6808
Last Price 1.5400
52-Week Low 0.7912

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar